Andrew D Badley

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1339454/publications.pdf

Version: 2024-02-01

176 papers	7,151 citations	53794 45 h-index	76900 74 g-index
212 all docs	212 docs citations	212 times ranked	8181 citing authors

#	Article	IF	Citations
1	Calm before the Storm. New England Journal of Medicine, 2022, 386, 479-485.	27.0	6
2	The Female-Predominant Persistent Immune Dysregulation of the Post-COVID Syndrome. Mayo Clinic Proceedings, 2022, 97, 454-464.	3.0	52
3	Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial. Lancet Respiratory Medicine,the, 2022, 10, 237-246.	10.7	50
4	Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records. JAMA Network Open, 2022, 5, e227038.	5.9	23
5	Could proteasome inhibition improve therapeutic vaccine response in HIV?. Vaccine, 2022, , .	3.8	0
6	Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection. , 2022, 1, .		6
7	Durability analysis of the highly effective BNT162b2 vaccine against COVID-19. , 2022, 1, .		8
8	SARS-CoV-2 and influenza coinfection throughout the COVID-19 pandemic: an assessment of coinfection rates, cohort characteristics, and clinical outcomes. , 2022, 1, .		13
9	Safety and efficacy of (+)â€epicatechin in subjects with Friedreich's ataxia: A phase <scp>II</scp>, openâ€label, prospective study. Journal of Inherited Metabolic Disease, 2021, 44, 502-514.	3.6	15
10	Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients. EClinicalMedicine, 2021, 33, 100774.	7.1	30
11	The long road to TRAIL therapy: a TRAILshort detour. Oncotarget, 2021, 12, 589-591.	1.8	0
12	Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research. Mayo Clinic Proceedings, 2021, 96, 601-618.	3.0	20
13	Healthcare disparities among anticoagulation therapies for severe COVIDâ€19 patients in the multiâ€site VIRUS registry. Journal of Medical Virology, 2021, 93, 4303-4318.	5.0	8
14	In Reply â€" Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019. Mayo Clinic Proceedings, 2021, 96, 817-818.	3.0	1
15	Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients. Cell Death Discovery, 2021, 7, 55.	4.7	34
16	The Yin and Yang of SARS-CoV-2 Mutation and Evolution. Mayo Clinic Proceedings, 2021, 96, 863-865.	3.0	4
17	Pre-existing conditions are associated with COVID-19 patientsâ€™ hospitalization, despite confirmed clearance of SARS-CoV-2 virus. EClinicalMedicine, 2021, 34, 100793.	7.1	14
18	Association Between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients With COVID-19. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 442-446.	2.4	9

#	Article	IF	Citations
19	In replyâ€"Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research. Mayo Clinic Proceedings, 2021, 96, 1092-1093.	3.0	3
20	Prior Statin Use and Risk of Mortality and Severe Disease From Coronavirus Disease 2019: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases, 2021, 8, ofab284.	0.9	11
21	Liver transplantation for acute liver failure in a SARS-CoV-2 PCR-positive patient. American Journal of Transplantation, 2021, 21, 2890-2894.	4.7	23
22	The Combination of Venetoclax and Ixazomib Selectively and Efficiently Kills HIV-Infected Cell Lines but Has Unacceptable Toxicity in Primary Cell Models. Journal of Virology, 2021, 95, .	3.4	14
23	A Blueprint to Control the SARS-CoV-2 Pandemic. Mayo Clinic Proceedings, 2021, 96, 1128-1131.	3.0	0
24	Cerebral Venous Sinus Thrombosis is not Significantly Linked to COVID-19 Vaccines or Non-COVID Vaccines in a Large Multi-State Health System. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105923.	1.6	31
25	Mass Spectrometric Analysis of Urine from COVID-19 Patients for Detection of SARS-CoV-2 Viral Antigen and to Study Host Response. Journal of Proteome Research, 2021, 20, 3404-3413.	3.7	35
26	Mapping each pre-existing conditionâ€™s association to short-term and long-term COVID-19 complications. Npj Digital Medicine, 2021, 4, 117.	10.9	19
27	Vaccination Safety. Mayo Clinic Proceedings, 2021, 96, 1712-1713.	3.0	2
28	Anemia during SARS-CoV-2 infection is associated with rehospitalization after viral clearance. IScience, 2021, 24, 102780.	4.1	4
29	FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med, 2021, 2, 979-992.e8.	4.4	127
30	Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. Med, 2021, 2, 965-978.e5.	4.4	40
31	Casirivimabâ€"Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. EClinicalMedicine, 2021, 40, 101102.	7.1	116
32	Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19. Journal of Clinical Investigation, 2021, 131, .	8.2	40
33	Acute Kidney Injury in Severe COVID-19 Has Similarities to Sepsis-Associated Kidney Injury. Mayo Clinic Proceedings, 2021, 96, 2561-2575.	3.0	41
34	Statins as an adjunctive therapy for COVID-19: the biological and clinical plausibility. Immunopharmacology and Immunotoxicology, 2021, 43, 37-50.	2.4	17
35	C-REACTIVE PROTEIN AS A BIOMARKER FOR IMPROVED EFFICACY OF LENZILUMAB IN PATIENTS WITH COVID-19: RESULTS FROM THE LIVE-AIR TRIAL. Chest, 2021, 160, A2522-A2524.	0.8	1
36	Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19. JAMA Network Open, 2021, 4, e2132540.	5.9	68

#	Article	IF	Citations
37	Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo. EClinicalMedicine, 2021, 42, 101225.	7.1	5
38	Mechanisms of Human Immunodeficiency Virus-Associated Lymphocyte Regulated Cell Death. AIDS Research and Human Retroviruses, 2020, 36, 101-115.	1.1	13
39	Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System. Hypertension, 2020, 76, 1350-1367.	2.7	46
40	Reactivating latent HIV with PKC agonists induces resistance to apoptosis and is associated with phosphorylation and activation of BCL2. PLoS Pathogens, 2020, 16, e1008906.	4.7	25
41	Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells. Clinical Cancer Research, 2020, 26, 5759-5771.	7.0	5
42	Research Response to SARS-CoV-2/COVID-19. Mayo Clinic Proceedings, 2020, 95, S52-S55.	3.0	8
43	GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia. Mayo Clinic Proceedings, 2020, 95, 2382-2394.	3.0	77
44	Benchmarking evolutionary tinkering underlying humanâ€“viral molecular mimicry shows multiple host pulmonaryâ€“arterial peptides mimicked by SARS-CoV-2. Cell Death Discovery, 2020, 6, 96.	4.7	37
45	Long-term SARS-CoV-2 RNA shedding and its temporal association to IgG seropositivity. Cell Death Discovery, 2020, 6, 138.	4.7	41
46	COVID-19 Ethics and Research. Mayo Clinic Proceedings, 2020, 95, 1119-1123.	3.0	40
47	Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis. ELife, 2020, 9, .	6.0	100
48	Inference from longitudinal laboratory tests characterizes temporal evolution of COVID-19-associated coagulopathy (CAC). ELife, 2020, 9, .	6.0	19
49	The Role of the BCL-2 Family of Proteins in HIV-1 Pathogenesis and Persistence. Clinical Microbiology Reviews, 2019, 33, .	13.6	31
50	TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection. Journal of Immunology, 2019, 203, 718-724.	0.8	5
51	Risks and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with HIV Infection. Biology of Blood and Marrow Transplantation, 2019, 25, e260-e267.	2.0	11
52	Translation to Practice: Accelerating the Cycle of Innovation to Impact. Mayo Clinic Proceedings, 2019, 94, 490-499.	3.0	2
53	HIV elite control is associated with reduced TRAILshort expression. Aids, 2019, 33, 1757-1763.	2.2	5
54	HIV Protease-Generated Casp8p41, When Bound and Inactivated by Bcl2, Is Degraded by the Proteasome. Journal of Virology, 2018, 92, .	3.4	19

#	Article	IF	Citations
55	Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment. Journal of Immunology, 2018, 200, 1110-1123.	0.8	12
56	Outcomes and Risks of Autologous Hematopoietic Stem Cell Transplant for Hematological Malignancies in Patients with HIV Infection. Biology of Blood and Marrow Transplantation, 2018, 24, S136.	2.0	0
57	Transient Loss of HIV-1 DNA in an HIV-1 Positive Patient After Kidney Transplantation: A Case Report. American Journal of Medicine, 2018, 131, e423-e424.	1.5	0
58	Allogeneic stem cell transplantation alone is unlikely to provide the HIV-1 cure. Future Virology, 2018, 13, 307-308.	1.8	0
59	The TRAIL: TRAILshort Axis in HIV Immunopathology. Critical Reviews in Immunology, 2018, 38, 491-503.	0.5	1
60	Lymphocyte Apoptosis. , 2018, , 1237-1253.		0
61	Cardiothoracic Transplant Recipient Mycoplasma hominis : An Uncommon Infection with Probable Donor Transmission. EBioMedicine, 2017, 19, 84-90.	6.1	32
62	Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition. Journal of Virology, 2017, 91, .	3.4	54
63	Increasing procaspase 8 expression using repurposed drugs to induce HIV infected cell death in ex vivo patient cells. PLoS ONE, 2017, 12, e0179327.	2.5	3
64	Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study. PLoS Medicine, 2017, 14, e1002461.	8.4	50
65	Casp8p41: The Protean Mediator of Death in CD4 T-cells that Replicate HIV. Journal of Cell Death, 2016, 9, JCD.S39872.	0.8	2
66	Disseminated Mycobacterium chimaera Infection After Cardiothoracic Surgery. Open Forum Infectious Diseases, 2016, 3, ofw131.	0.9	58
67	Prime, Shock, and Kill: Priming CD4 T Cells from HIV Patients with a BCL-2 Antagonist before HIV Reactivation Reduces HIV Reservoir Size. Journal of Virology, 2016, 90, 4032-4048.	3.4	85
68	Twenty years of human immunodeficiency virus care at the Mayo Clinic: Past, present and future. World Journal of Virology, 2016, 5, 63.	2.9	4
69	Can HIV Be Cured and Should We Try?. Mayo Clinic Proceedings, 2015, 90, 705-709.	3.0	5
70	Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. EBioMedicine, 2015, 2, 706-712.	6.1	20
71	Casp8p41 and HIV. Oncotarget, 2015, 6, 23042-23043.	1.8	3
72	Short Communication: CD4 T Cell Declines Occurring During Suppressive Antiretroviral Therapy Reflect Continued Production of Casp8p41. AIDS Research and Human Retroviruses, 2014, 30, 476-479.	1.1	12

#	Article	IF	Citations
73	Choice of antiretroviral therapy differentially impacts survival of HIV-infected CD4 T cells. Molecular and Cellular Therapies, 2014, 2, 1.	0.2	34
74	Casp8p41 generated by HIV protease kills CD4 T cells through direct Bak activation. Journal of Cell Biology, 2014, 206, 867-876.	5.2	28
75	Making sense of how HIV kills infected CD4 T cells: implications for HIV cure. Molecular and Cellular Therapies, 2014, 2, 20.	0.2	22
76	â€œMuch ado to achieve nothing: prospects for curing HIV infectionâ€• Molecular and Cellular Therapies, 2014, 2, 9.	0.2	0
77	Lymphocyte Apoptosis. , 2014, , 1-19.		0
78	Anti-apoptotic mechanisms of HIV: lessons and novel approaches to curing HIV. Cellular and Molecular Life Sciences, 2013, 70, 3355-3363.	5.4	30
79	Altering cell death pathways as an approach to cure HIV infection. Cell Death and Disease, 2013, 4, e718-e718.	6.3	73
80	Heme oxygenaseâ€1 regulates the immune response to influenza virus infection and vaccination in aged mice. FASEB Journal, 2012, 26, 2911-2918.	0.5	43
81	SDF-1Î± Degrades whereas Glycoprotein 120 Upregulates Bcl-2 Interacting Mediator of Death Extralong Isoform: Implications for the Development of T Cell Memory. Journal of Immunology, 2012, 189, 1835-1842.	0.8	6
82	Sepsis Syndrome. , 2012, , 274-279.		0
83	Human Immunodeficiency Virus Envelope Protein Gp120 Induces Proliferation but Not Apoptosis in Osteoblasts at Physiologic Concentrations. PLoS ONE, 2011, 6, e24876.	2.5	8
84	The HIV-1-Specific Protein Casp8p41 Induces Death of Infected Cells through Bax/Bak. Journal of Virology, 2011, 85, 7965-7975.	3.4	32
85	Isolation of a TRAIL Antagonist from the Serum of HIV-infected Patients*. Journal of Biological Chemistry, 2011, 286, 35742-35754.	3.4	16
86	TRAIL Dependent Fratricidal Killing of gp120 Primed Hepatocytes by HCV Core Expressing Hepatocytes. PLoS ONE, 2011, 6, e27171.	2.5	6
87	Cytomegalovirus Infection. , 2011, , 111.		0
88	Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals. Aids, 2010, 24, 2639-2644.	2.2	5
89	How Much Gp120 Is There?. Journal of Infectious Diseases, 2010, 201, 1273-1274.	4.0	27
90	Intracellular Casp8p41 Content Is Inversely Associated with CD4 T Cell Count. Journal of Infectious Diseases, 2010, 202, 386-391.	4.0	13

#	Article	IF	Citations
91	Patients with Discordant Responses to Antiretroviral Therapy Have Impaired Killing of HIV-Infected T Cells. PLoS Pathogens, 2010, 6, e1001213.	4.7	21
92	Casp8p41 expression in primary T cells induces a proinflammatory response. Aids, 2010, 24, 1251-1258.	2.2	5
93	CXCR4 Tropic HIV-1 gp120 Inhibition of SDF-1Î±-Induced Chemotaxis Requires Lck and is Associated with Cofilin Phosphorylation~!2010-04-23~!2010-05-24~!2010-06-23~!. The Open Virology Journal, 2010, 4, 157-162.	1.8	7
94	HIV gp120 Induces, NF-ÎºB Dependent, HIV Replication that Requires Procaspase 8. PLoS ONE, 2009, 4, e4875.	2.5	19
95	HIVâ€1 Tat Protein Suppresses Cholangiocyte Tollâ€Like Receptor 4 Expression and Defense againstCryptosporidium parvum. Journal of Infectious Diseases, 2009, 199, 1195-1204.	4.0	36
96	Nelfinavir/ritonavir reduces acinar injury but not inflammation during mouse caerulein pancreatitis. American Journal of Physiology - Renal Physiology, 2009, 296, G1040-G1046.	3.4	20
97	The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases. Anti-Infective Agents in Medicinal Chemistry, 2009, 8, 87-101.	0.6	17
98	The TRAIL to Viral Pathogenesis: The Good, the Bad and the Ugly. Current Molecular Medicine, 2009, 9, 495-505.	1.3	58
99	HIV Induces TRAIL Sensitivity in Hepatocytes. PLoS ONE, 2009, 4, e4623.	2.5	51
100	CD4 T Cells Treated with gp120 Acquire a CD45R0+/CD45RA+ Phenotype. The Open Virology Journal, 2009, 3, 21-25.	1.8	5
101	HIV Protease Inhibitors Impact on Apoptosis. Medicinal Chemistry, 2008, 4, 75-79.	1.5	33
102	Beneficial Effect of TRAIL on HIV Burden, without Detectable Immune Consequences. PLoS ONE, 2008, 3, e3096.	2.5	11
103	HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice. Journal of Clinical Investigation, 2008, 118, 2025-38.	8.2	56
104	Infected Cell Killing by HIV-1 Protease Promotes NF-ÎºB Dependent HIV-1 Replication. PLoS ONE, 2008, 3, e2112.	2.5	26
105	Analysis of HIV Protease Killing Through Caspase 8 Reveals a Novel Interaction Between Caspase 8 and Mitochondria. The Open Virology Journal, 2008, 1, 39-46.	1.8	23
106	HIV Protease Cleavage of Procaspase 8 is Necessary for Death of HIVInfected Cells. The Open Virology Journal, 2008, 2, 1-7.	1.8	29
107	Nelfinavir monotherapy increases naive T-cell numbers in HIV-negative healthy young adults. Frontiers in Bioscience - Landmark, 2008, 13, 1605.	3.0	7
108	Renal upregulation of HO-1 reduces albumin-driven MCP-1 production: implications for chronic kidney disease. American Journal of Physiology - Renal Physiology, 2007, 292, F837-F844.	2.7	40

#	Article	IF	Citations
109	The Human Immunodeficiency Virus Type 1 Tat Protein Enhances Cryptosporidium parvum -Induced Apoptosis in Cholangiocytes via a Fas Ligand-Dependent Mechanism. Infection and Immunity, 2007, 75, 684-696.	2.2	20
110	Glycoprotein 120 Binding to CXCR4 Causes p38-Dependent Primary T Cell Death That Is Facilitated by, but Does Not Require Cell-Associated CD4. Journal of Immunology, 2007, 178, 4846-4853.	0.8	36
111	Human Immunodeficiency Virus Type 1 Protease Cleaves Procaspase 8 In Vivo. Journal of Virology, 2007, 81, 6947-6956.	3.4	61
112	Renal Hemodynamic, Inflammatory, and Apoptotic Responses to Lipopolysaccharide in HO-1â^'/â^' Mice. American Journal of Pathology, 2007, 170, 1820-1830.	3.8	67
113	Flying in the Face of Resistance: Antiviral-independent Benefit of HIV Protease Inhibitors on T-cell Survival. Clinical Pharmacology and Therapeutics, 2007, 82, 294-299.	4.7	21
114	HIV protease inhibitors modulate apoptosis signaling in vitro and in vivo. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 969-977.	4.9	37
115	Disseminated coccidioidomycosis in a liver transplant recipient with negative serology: Use of polymerase chain reaction. Liver Transplantation, 2006, 12, 1290-1292.	2.4	21
116	Acquired T-cell sensitivity to TRAIL mediated killing during HIV infection is regulated by CXCR4-gp120 interactions. Aids, 2005, 19, 1125-1133.	2.2	26
117	Increased thymic output in HIV-negative patients after antiretroviral therapy. Aids, 2005, 19, 1467-1472.	2.2	6
118	MCP-1 is up-regulated in unstressed and stressed HO-1 knockout mice: Pathophysiologic correlates1. Kidney International, 2005, 68, 611-622.	5.2	98
119	Elimination of Senescent Neutrophils by TNF-Related Apoptosis-Inducing Ligand. Journal of Immunology, 2005, 175, 1232-1238.	0.8	68
120	Human Immunodeficiency Virus Reactivation by Phorbol Esters or T-Cell Receptor Ligation Requires both PKCÎ± and PKCÎ¸. Journal of Virology, 2005, 79, 9821-9830.	3.4	51
121	Blockade of HERG channels by HIV protease inhibitors. Lancet, The, 2005, 365, 682-686.	13.7	162
122	Ritonavir does not inhibit calpain in vitro. Biochemical and Biophysical Research Communications, 2005, 327, 208-211.	2.1	12
123	Rejection Severity Directly Correlates With Myocyte Apoptosis in Pig-to-Baboon Cardiac Xenotransplantation. Journal of Heart and Lung Transplantation, 2005, 24, 841-847.	0.6	10
124	Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor. Journal of Clinical Investigation, 2005, 115, 1828-1838.	8.2	84
125	Vpr. , 2005, , 109-126.		0
126	HIV Protease (PR) and Cell Death. , 2005, , 155-168.		1

#	Article	IF	Citations
127	Direct Effects of Anti-HIV Therapeutics on Apoptosis. , 2005, , 441-445.		0
128	Differential Effects of Interleukin-7 and Interleukin-15 on NK Cell Anti-Human Immunodeficiency Virus Activity. Journal of Virology, 2004, 78, 6033-6042.	3.4	54
129	Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis. FASEB Journal, 2004, 18, 1185-1191.	0.5	80
130	Assessment of drug-drug interaction potential of enfuvirtide in human immunodeficiency virus type 1?infected patients*1. Clinical Pharmacology and Therapeutics, 2004, 75, 558-568.	4.7	33
131	Impact of mitochondrial regulation of apoptosis on the pathogenesis and treatment of HIV-1-induced immunodeficiency. Mitochondrion, 2004, 4, 235-254.	3.4	8
132	Cordyceps sinensis extracts do not prevent Fas-receptor and hydrogen peroxide-induced T-cell apoptosis. Journal of Ethnopharmacology, 2004, 90, 57-62.	4.1	23
133	Effect on CD4 T-cell count of replacing protease inhibitors in patients with successful HIV suppression. Aids, 2004, 18, 693-695.	2.2	6
134	Assessment of Metabolic Inhibition Potential of Enfuvirtide Using a 5-Drug Cocktail in HIV-1 Infected Patients. Clinical Pharmacology and Therapeutics, 2003, 73, P81-P81.	4.7	8
135	Mitochondrion-mediated apoptosis in HIV-1 infection. Trends in Pharmacological Sciences, 2003, 24, 298-305.	8.7	49
136	Production of CD8+T Cell Nonlytic Suppressive Factors by CD28, CD38, and HLA-DR Subpopulations. AIDS Research and Human Retroviruses, 2003, 19, 497-502.	1.1	6
137	Attenuated T-Lymphocyte Response to HIV Therapy in Individuals Receiving HMG-CoA Reductase Inhibitors. HIV Clinical Trials, 2003, 4, 164-169.	2.0	21
138	Resistance to Apoptosis: Mechanism for the Development of HIV Reservoirs. Current HIV Research, 2003, 1, 261-274.	0.5	24
139	Vpr R77Q is associated with long-term nonprogressive HIV infection and impaired induction of apoptosis. Journal of Clinical Investigation, 2003, 111, 1547-1554.	8.2	174
140	Normalization of natural killer cell function and phenotype with effective anti-HIV therapy and the role of IL-10. Aids, 2002, 16, 1251-1256.	2.2	71
141	Influence of mitochondrial control of apoptosis on the pathogenesis, complications and treatment of HIV infection. Biochimie, 2002, 84, 251-264.	2.6	14
142	Comparative CD4 T-Cell Responses of Reverse Transcriptase Inhibitor Therapy With or Without Nelfinavir Matched for Viral Exposure. HIV Clinical Trials, 2001, 2, 160-170.	2.0	18
143	Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood, 2001, 98, 1078-1085.	1.4	130
144	Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. Aids, 2001, 15, 1749-1756.	2.2	215

#	Article	IF	Citations
145	Induction of Cell Death in Human Immunodeficiency Virus-Infected Macrophages and Resting Memory CD4 T Cells by TRAIL/Apo2L. Journal of Virology, 2001, 75, 11128-11136.	3.4	106
146	Effect of Cessation of Highly Active Antiretroviral Therapy during a Discordant Response: Implications for Scheduled Therapeutic Interruptions. Clinical Infectious Diseases, 2001, 33, 344-348.	5.8	14
147	Flow cytometric measurement of telomere length. Cytometry, 2000, 42, 159-164.	1.8	39
148	Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease. British Journal of Clinical Pharmacology, 2000, 50, 108-115.	2.4	56
149	Mechanisms of HIV-associated lymphocyte apoptosis. Blood, 2000, 96, 2951-2964.	1.4	254
150	Decreased HIV-Associated T Cell Apoptosis by HIV Protease Inhibitors. AIDS Research and Human Retroviruses, 2000, 16, 559-567.	1.1	97
151	A drug interaction between fusidic acid and a combination of ritonavir and saquinavir. British Journal of Clinical Pharmacology, 2000, 50, 83-84.	2.4	17
152	THE ECONOMIC IMPACT OF CYTOMEGALOVIRUS INFECTION AFTER LIVER TRANSPLANTATION. Transplantation, 2000, 69, 357-361.	1.0	75
153	Mechanisms of HIV-associated lymphocyte apoptosis. Blood, 2000, 96, 2951-2964.	1.4	20
154	<title>Dewetting of adsorbed protein on polystyrene and graphite surfaces during drying</title>. , 1999, , .		1
155	Activation-Induced CD4+ T Cell Death in HIV-Positive Individuals Correlates with Fas Susceptibility, CD4+ T Cell Count, and HIV Plasma Viral Copy Number. AIDS Research and Human Retroviruses, 1999, 15, 1509-1518.	1.1	50
156	Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death and Differentiation, 1999, 6, 420-432.	11.2	94
157	Porphyria Cutanea Tarda and Human Immunodeficiency Virus: Two Cases Associated With Hepatitis C. Mayo Clinic Proceedings, 1998, 73, 895-897.	3.0	11
158	Transcriptional Regulation of the Human FasL Promoter-Enhancer Region. Journal of Biological Chemistry, 1998, 273, 4416-4423.	3.4	141
159	SIGNIFICANCE OF CYTOMEGALOVIRUS FOR LONG-TERM SURVIVAL AFTER ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation, 1998, 66, 1020-1028.	1.0	66
160	The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection.. Journal of Clinical Investigation, 1998, 101, 2394-2405.	8.2	116
161	In vivo analysis of Fas/FasL interactions in HIV-infected patients.. Journal of Clinical Investigation, 1998, 102, 79-87.	8.2	141
162	Macrophage-dependent Apoptosis of CD4+ T Lymphocytes from HIV-infected Individuals Is Mediated by FasL and Tumor Necrosis Factor. Journal of Experimental Medicine, 1997, 185, 55-64.	8.5	241

#	Article	IF	Citations
163	Seroconversion to Human Herpesvirus 6 following Liver Transplantation Is a Marker of Cytomegalovirus Disease. Journal of Infectious Diseases, 1997, 176, 1135-1140.	4.0	121
164	Apoptosis in AIDS. Advances in Pharmacology, 1997, 41, 271-294.	2.0	18
165	PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION IN LIVER TRANSPLANTATION. Transplantation, 1997, 64, 66-73.	1.0	78
166	Infectious Rates of Central Venous Pressure Catheters: Comparison Between Newly Placed Catheters and Those That Have Been Changed. Mayo Clinic Proceedings, 1996, 71, 838-846.	3.0	31
167	Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder. Liver Transplantation, 1996, 2, 375-382.	1.8	71
168	Long-Term Follow-Up of Multifocal Osteoarticular Sporotrichosis Treated with Itraconazole. Clinical Infectious Diseases, 1996, 23, 394-395.	5.8	19
169	Prognostic Significance and Risk Factors of Untreated Cytomegalovirus Viremia in Liver Transplant Recipients. Journal of Infectious Diseases, 1996, 173, 446-449.	4.0	35
170	RELEVANCE AND RISK FACTORS OF ENTEROCOCCAL BACTEREMIA FOLLOWING LIVER TRANSPLANTATION1. Transplantation, 1996, 61, 1192-1197.	1.0	47
171	RISK FACTORS OF INVASIVE CANDIDA AND NON-CANDIDA FUNGAL INFECTIONS AFTER LIVER TRANSPLANTATION1. Transplantation, 1996, 62, 926-934.	1.0	180
172	Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. Journal of Virology, 1996, 70, 199-206.	3.4	307
173	26-Year-Old Man With HIV Infection and Abdominal Pain. Mayo Clinic Proceedings, 1995, 70, 885-888.	3.0	0
174	A model of food-borne Listeria monocytogenes infection in the Sprague-Dawley rat using gastric inoculation: development and effect of gastric acidity on infective dose. International Journal of Food Microbiology, 1993, 18, 15-24.	4.7	81
175	Enoxaparin Is Associated With Lower Rates of Thrombosis, Kidney Injury, and Mortality Than Unfractionated Heparin in Hospitalized COVID Patients. SSRN Electronic Journal, 0, , .	0.4	2
176	Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19. , 0, , .		1